Xilio Therapeutics, Inc.
XLO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $51,103 | $15,123 | $73,685 | $437,734 |
| - Cash | $55,291 | $44,704 | $120,385 | $198,053 |
| + Debt | $8,142 | $11,457 | $19,939 | $20,536 |
| Enterprise Value | $3,954 | -$18,124 | -$26,761 | $260,217 |
| Revenue | $6,344 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $6,344 | $0 | $0 | -$1,499 |
| % Margin | 100% | – | – | – |
| EBITDA | -$58,001 | -$77,233 | -$87,302 | -$73,701 |
| % Margin | -914.3% | – | – | – |
| Net Income | -$58,241 | -$76,404 | -$88,222 | -$75,800 |
| % Margin | -918% | – | – | – |
| EPS Diluted | -1.09 | -2.78 | -3.19 | -2.72 |
| % Growth | 60.8% | 12.9% | -17.3% | – |
| Operating Cash Flow | -$18,378 | -$68,620 | -$75,723 | -$80,751 |
| Capital Expenditures | -$36 | -$486 | -$1,867 | -$1,100 |
| Free Cash Flow | -$18,414 | -$69,106 | -$77,590 | -$81,851 |